Adam Fung

Adam Fung has extensive experience in the biotechnology and pharmaceutical industry. Adam currently holds the position of Sr. Director, CMC Strategy at Cabaletta Bio since January 2023. Prior to this, they worked at Beam Therapeutics as Sr. Director, Product Quality Lead; Cell Therapy from April 2022 to November 2022.

From April 2019 to April 2022, Adam was employed at Bristol Myers Squibb as Director, Global Product Quality; CAR-T Cell Therapy. Before that, they held the roles of Director, Analytical Development and Director, Quality Control at Omeros Corporation from October 2016 to March 2019.

Adam's earlier career includes a position as Principal Scientist and Group Leader - Analytical Development at Agensys, Inc. from December 2014 to September 2016. Adam also worked at Seattle Genetics as a Senior Scientist - Analytical Biochemistry from September 2011 to December 2014, and as a Scientist - Analytical Biochemistry from September 2008 to September 2011.

Their first role in the industry was as a Research Associate at ZymoGenetics from September 2002 to August 2003. Overall, Adam Fung has a diverse background and has held various leadership positions in the biotech and pharmaceutical field.

Adam Fung holds a Ph.D. in Biochemistry/Biophysics from the University of Maryland, which they obtained from 2003 to 2008. Prior to that, they earned a Bachelor of Science (B.S.) degree in Biochemistry from Western Washington University, which they completed from 1999 to 2002.